Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN(a)-Outcomes olpasiran cardiovascular outcomes trial
NL-OMON60300Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- May 2023
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and lipoprotein(a) hyperlipoproteinemia (Lp(a)) comparing Olpasiran with Placebo (2 arms). Primary endpoint: Major coronary event composite. Started May 2023; status: active, not recruiting.
02
Drugs
olpasiran
03
Conditions
atherosclerotic diseaselipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on NL-OMON60300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60300.